STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We’ve got some big acquisition news today, and also some politics — specifically a look at how pharma lobbyists, who have longed considered the FDA something of a fortress, now see real opportunity to exert influence.

Also, read up on a Phase 3 miss from Gossamer Bio, and why it’s going to seek an approval anyway.

Continue to STAT+ to read the full story…